Physician profile
Julia E Fehniger
NPI 1245679984
$4,094.37
in general payments reported to CMS, 2019-2025
12 companies · $86.04 in 2025
The $86.04 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2021: $128 · 2023: $2,773 · 2024: $192 · 2025: $86.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $424 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $424.19 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,619.33 | 2023 | Jemperli, Zejula |
| Medical Device Business Services, INC. | $887.50 | 2019 | |
| Merck Sharp & Dohme LLC | $186.61 | 2019-2024 | Lynparza |
| Intuitive Surgical, INC. | $153.49 | 2023 | |
| Eisai INC. | $91.93 | 2021 | |
| Seagen INC. | $36.48 | 2021 | |
| Abbvie INC. | $32.99 | 2024 | |
| Corcept Therapeutics | $32.45 | 2025 | Korlym |
| Pfizer INC. | $27.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.33 | 2025 | Enhertu |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Fehniger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.